Chemotherapy with or without lisaftoclax for low-risk acute myeloid leukemia
Compares chemotherapy with and without lisaftoclax in low-risk acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-65 with newly diagnosed acute myeloid leukemia (AML) who can have intensive chemotherapy.
- Age
- 18-65 years
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed AML (WHO classification), intermediate- or adverse-risk by ELN 2022 genetic risk stratification.
- Earlier treatment
- Cannot have had BCL-2 inhibitors or hypomethylating agents before.
Main reasons for not taking part
- Acute promyelocytic leukemia
- Leukemia in the central nervous system
- Another cancer in the past 5 years
- Positive for HIV
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07651176, who can take part
Where in China
- The First Affiliated Hospital of Zhejiang UniversityHangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- First Affiliated Hospital of Zhejiang University
- Trial code
- NCT07651176
- Record updated
- 16 June 2026
- Original description
This is a phase II/III, multicenter, randomized, three-arm, open-label, parallel controlled trial. The primary objective of this study is to compare the 2-years EFS rate of the LDA, LHAA, and DA regimens in newly diagnosed patients with low-risk acute myeloid leukemia who are eligible for intensive chemotherapy.Read full original descriptionShow less
A Multicenter, Prospective, Randomized Controlled Clinical Study Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
This is a phase II/III, multicenter, randomized, three-arm, open-label, parallel controlled trial. The primary objective of this study is to compare the 2-years EFS rate of the LDA, LHAA, and DA regimens in newly diagnosed patients with low-risk acute myeloid leukemia who are eligible for intensive chemotherapy.
Inclusion: Newly diagnosed acute myeloid leukemia (AML) confirmed according to the World Health Organization (WHO) classification; Classified as intermediate- or adverse-risk AML based on the European LeukemiaNet (ELN) 2022 genetic risk stratification; Age 18-65 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; Adequate hepatic and renal function: total bilirubin ≤2 mg/dL (35 μmol/L); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2× the upper limit of normal; serum creatinine ≤177 μmol/L; Normal cardiac function, defined as left ventricular ejection fraction (LVEF) >50%; Life expectancy ≥3 months; Signed written informed consent by the patient or their legally authorized representative prior to study enrollment.
Exclusion: Prior treatment with B-cell lymphoma 2 (BCL-2) inhibitors or hypomethylating agents, or current participation in any other investigational drug study; History of other malignancies within the past 5 years; Positive for human immunodeficiency virus (HIV); Presence of any other serious medical condition that may limit study participation, including advanced infections, uncontrolled diabetes mellitus, severe cardiac insufficiency, or angina; Ineligible for intensive chemotherapy due to poor general condition; Inability to take oral medication or presence of malabsorption syndrome; Acute promyelocytic leukemia; Central nervous system involvement by leukemia; Pregnant or breastfeeding women; Inability to understand or comply with the study protocol; Inability or unwillingness to provide written informed consent.